Focus: Ekso Bionics is a public medical device company specializing in wearable exoskeleton technology for spinal cord injury rehabilitation and mobility restoration. The company operates at modest scale with $18M in annual revenue and a focus on robotic-assisted therapy applications.
Profile data last refreshed 8h ago · AI intelligence enriched 1mo ago
No open roles listed right now. Follow Ekso Bionics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Ekso Bionics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Ekso Bionics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
8-K Filing: ChronoScale Holdings Corp (CHRN) (CIK 0001549084) — EX-10.1
EX-10.1
NuvOx Therapeutics, Clinical-Stage Oxygen Therapeutics Developer, Files for NYSE American IPO - TradingView
NuvOx Therapeutics, Clinical-Stage Oxygen Therapeutics Developer, Files for NYSE American IPO TradingView
Ekso Bionics Holdings Stock (US2826641040): Ticker Change To ChronoScale Raises Questions For Legacy - AD HOC NEWS
Ekso Bionics Holdings Stock (US2826641040): Ticker Change To ChronoScale Raises Questions For Legacy AD HOC NEWS
Ekso Bionics Holdings stock (US2826641040): How the exoskeleton pioneer is navigating 2026 - AD HOC NEWS
Ekso Bionics Holdings stock (US2826641040): How the exoskeleton pioneer is navigating 2026 AD HOC NEWS
Exoskeleton Market to Reach $20.3 Billion by 2035 at 22.4% CAGR | - openPR.com
Exoskeleton Market to Reach $20.3 Billion by 2035 at 22.4% CAGR | openPR.com
8-K Filing: ChronoScale Corp (CHRN) (CIK 0001549084) — EX-99.2
EX-99.2
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Walking improvement in chronic incomplete spinal cord injury with exoskeleton robotic training (WISE): a randomized controlled trial.
Comparison of peak oxygen consumption response to aquatic and robotic therapy in individuals with chronic motor incomplete spinal cord injury: a randomized controlled trial.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo